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Abstract 
Graves’ orbitopathy, also known as thyroid eye disease or thyroid-associated orbitopathy, is 
visually disabling, cosmetically disfiguring and has a substantial negative impact on a patients’ 
quality of life. There is increasing awareness of the need for early diagnosis and rapid specialist 
input from endocrinologists and ophthalmologists. Glucocorticoids are the mainstay of 
treatment; however, recurrence occurs frequently once these are withdrawn. Furthermore, in 
>60% of cases, normal orbital anatomy is not restored, and skilled rehabilitative surgery is 
required to reduce disfigurement, double vision and occasionally, to preserve vision. Clinical 
trials from over the past decade [Au: edits to define “recent” OK? Please edit my changes if I 
have misunderstood you This is fine] have shown that considerable benefit can be derived from 
the addition of anti-proliferative agents (such as mycophenolate or azathioprine) in preventing 
deterioration after steroid cessation. In addition, targeted biologic therapies have shown promise, 
including teprotumumab (anti-IGF-1R), which seems to substantially reduce proptosis, rituximab 
(anti-CD20), which reduces inflammation, and tocilizumab, which potentially benefits both of 
these parameters. Other strategies such as orbital radiotherapy have had their widespread role in 
combination therapy called into question. In the last decade, the pathophysiology of Graves’ 
orbitopathy has also been revised with identification of new potential therapeutic targets. In this 
review we provide an up-to-date overview of the field, [Au: addition of linking text OK? This is 
fine] outline the optimal management of Graves’ orbitopathy and summarise the research 
developments in this area to highlight future research questions and direct future clinical trials. 
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[H1] Introduction [Au: Please ignore H1, H2 etc. These are heading markers for our production 
department that will be removed in the final proofs. H1 headings can have a maximum of 38 
characters, including spaces; H2 headings 38 characters; and H3 heading ~60 characters.]  
 
Graves’ orbitopathy [Au: We do not abbreviate terms that are fewer than 3 words, unless the 
term is within our style guide. GO is not in our style guide so I have removed it as an abbreviation. 
In addition, I find that manuscripts with fewer abbreviations are easier to read for non-experts 
Very happy with this change] is a rare complex autoimmune disorder which causes substantial 
morbidity
1
. The disorder can result in orbital disfigurement, double vision and even visual loss
2
. 
Consequently, Graves’ orbitopathy has a substantial negative effect on quality of life3, mental 
health
4
 and socioeconomic status of patients
5,6
. The vast majority, more than 90% [Au: Can you 
please define “vast majority” by providing a figure (e.g. is vast majority 70% or 90% etc.)added] 
of patients with Graves’ orbitopathy have Graves’ disease, [Au: As with GO, I have removed GD 
as an abbreviation this is fine] an inflammatory autoimmune condition that is caused by 
thyrotropin receptor auto-antibodies (TSH-R-Ab)
7
.  
 [Au: Large blocks for text can be difficult for readers to digest and so I have inserted a paragraph 
break here. If you disagree with the change, please feel free to revert. Agree with change]  
 [Au: I have made some edits to the following sentence for narrative flow. Please check that I 
have not altered your intended meaning. This is fine] Graves’ disease is common throughout the 
world. The disease, which predominantly affects women, typically in their third to fifth decade
8
, 
has an overall prevalence of 0.5%
8
. Around 15% of patients with Graves’ disease who do not have 
Graves’ orbitopathy at baseline will develop it, typically within 3-6 months on average. [Au: On 
average, how long does it take for patients to develop Graves’ orbitopathy from baseline? (years 
or months etc.). I think our readers would benefit from this information. See my example linking 
text, but feel free to use your own text added] Approximately 2% of patients who develop Graves’ 
orbitopathy will [Au: Addition for clarity OK? This is fine] develop moderate-severe disease
9,10
. 
A multicentre prospective study from 2018 [Au: We avoid the use of “recent” as it can be 
ambiguous for the reader. 2018 OK here? This is fine] proposed a predictive score of the risk 
of developing Graves’ orbitopathy in Graves’ disease with ocular inflammation at baseline; 
smoking, duration of thyroid dysfunction and especially the TSH-R-Ab titre were the four key 
risk factors
10
.This score, however, was more useful at identifying [Au: OK? This is fine] 
individuals who would not develop Graves’ orbitopathy during treatment for Graves’ disease 
rather than predicting which patients were at risk of developing Grave’s orbitopathy10. In October 
2009, the Amsterdam Declaration, signed by over 80 organisations, proposed that the incidence 
and morbidity due to Graves’ orbitopathy could be substantially reduced by preventive measures, 
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such as warning patients about the early symptoms of Graves’ orbitopathy, stopping smoking, 
avoiding hypothyroidism after radioactive iodine administration [ Au: Could you please provide 
1 or 2 examples of preventative measures here? Text added] and improved early access to 
specialist care
11
. 
 
In order to best understand the treatments and pathogenesis of Graves’ orbitopathy, it is 
important to know that most of the signs and symptoms of Graves’ orbitopathy can be explained 
by the expansion of the orbital contents. The orbital fibroblast
2
 is the target of a spectrum of 
autoimmune responses, which collectively promote proliferation, excess adipogenesis (formation 
of new fat cells by differentiation of fibroblasts) and over-production of extra-cellular matrix 
(ECM). The ECM comprises glycosaminoglycans (GAGs), such as chondroitin sulphate and 
hyaluronan, which is not sulphated but is able to absorb up to 1000 times its weight in water
12
.  
 
Glucocorticoids are the mainstay of treatment in Graves’ orbitopathy, however, the mechanism 
of action of high doses remains largely unexplained, and this needs to be balanced against their 
adverse effects
13
 . Although glucocorticoids are known to reduce inflammation and deplete 
leucocytes, a direct action on the adipocytes including the inhibition of ‘browning’ processes in 
orbital fat cells is possible
14
. In addition, studies indicate 11beta hydroxysteroid-Dehydrogenase 
[Au: OK? This is fine] expression might [Au: “May” can be ambiguous to the reader, we prefer 
to use “Might”, “Could,” “Can” etc. This is fine] also have a role in the development of Graves’ 
orbitopathy, possibly by local induction of adipogenesis 
15,16
. In the last decade, our understanding 
of the pathogenesis and treatment of Graves’ orbitopathy has improved as a result of both clinical 
trials and laboratory research. 
 
In this review we provide a detailed overview of the clinical and surgical management of Graves’ 
orbitopathy. We have focussed on trials from the past 3 years whose results provide insight into 
the pathogenetic mechanisms in operation. Finally, we deal with disease pathogenesis more 
broadly, to highlight possible future clinical trials and improvements to patient management. 
[Au: Can you please include a paragraph that sums up the aims of your Review. I have provided 
a few example ‘sentence starters’ that you can use, but please feel free to also suggest your own 
Sentences added.] 
  
 
[H1] Assessment of Graves’ orbitopathy 
5 
 
Due to the complex pathogenesis of Graves’ orbitopathy both visual function and cosmetic visual 
appearance [Au: by ‘visual appearance’ do you mean the physical appearance of a patient is 
affected or that the way in which a patients’ vision appears to them is affected? Can you please 
specify made clearer] can be affected; therefore several validated assessment scores are used to 
assess different components of the condition (Box 1 [Au: Of note, I have moved all of the boxes 
to the end of the manuscript so that they remain with the other display items This is fine] ). The 
two main current Graves’ orbitopathy classifications are from the European group on Graves’ 
orbitopathy
17
 (EUGOGO) and Vision, Inflammation, Strabismus, Appearance (VISA)
18
. [Au: 
Edits to the following sentence to improve clarity. Please check that I have not altered your 
intended meaning and feel free to edit my changes if I have misunderstood you changes are 
great] EUGOGO is the most common classification used in Europe, whereas VISA is the most 
common in USA and [Au: We avoid “/” in this context. is “and/or” OK here?slight change] 
Canada. Other scores include Clinical Activity Score (CAS)
19
 which focusses on the degree of 
inflammation, NOSPECS
20,21
 which is a useful mnemonic for assessing severity
20,21
 and 
Ophthalmopathy Index which assesses inflammation and visual function
22
.   [Au: Could you 
please introduce the other activity and severity scores in the opening paragraph of this section? 
e.g. Clinical Activity Score, NOSPECS and Ophthalmopathy Index. I think it might also be 
useful to introduce VISA-V,S,A (and define V,S,A) scales and VISA inflammation index as it is 
currently unclear if these are both part of VISA or separate entities. Added other scores here 
VISA added below]  
  
 
[Au: Paragraph break added here]  
The EUGOGO classification of disease severity is sight-threatening, moderate to severe and mild 
Graves’ orbitopathy. The aims of EUGOGO were to investigate newly introduced drugs on 
severity, signs and symptoms as well as on clinical activity. In addition, the validated EUGOGO 
quality of life questionnaire is a further relevant pillar to evaluate the efficacy of the tested drug. 
EUGOGO has introduced one score each for clinical activity (CAS) and severity (CSS)
23
.  The 
CAS component encompasses subjective symptoms i.e. pain and inflammatory signs i.e. swelling 
and redness. In comparison, CSS evaluates the magnitude of the exophthalmometer or proptosis 
values, lid retraction, diplopia grades and corneal involvement. The more “simplistic” VISA 
classification uses four signs only (Visual acuity, Inflammation, Strabismus or motility 
disturbances and Appearance) and therefore does not directly correlate with the EUGOGO CAS 
and CSS. A one-to-one direct comparison of both classifications is pending. It is therefore worth 
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noting that EUGOGO and VISA are not interchangeable
24
.[Au: Could you please add a similar 
description of the VISA classifications? I.e. what is the classification of disease activity in VISA? 
Are the VISA classifications split into VISA inflammation index and VISA-V,S,A score? If so, I 
think this should be explained here. More detailed explanation provided] [Au: why is this? Could 
you briefly explain. Is it because one classification system see above]. This distinction [Au: “This” 
needs to be followed by a noun. Distinction OK here? If not, please feel free to choose your 
own This is fine] is particularly important when interpreting their assessment of treatment 
responses in clinical trials.  
 
The Clinical Activity Score
19
 and the VISA Inflammation index component of the VISA 
classification [Au: OK? This is fine] 
18
 reflect disease activity, whereas the EUGOGO
17,25
, 
NOSPECS 
20,21
, VISA-V,S,A scales
18
, and Ophthalmopathy Index
22
 can all be used to assess 
severity including ocular deformity and visual dysfunction. The relative merits of these scores 
were [Au: Can you please define “recently” here by providing a time frame?] assessed elsewhere 
in 2015
24
.  
 
EUGOGO patient reported outcomes are also used to assess the effect of Graves’ orbitopathy 
[Au: addition of Graves’ orbitopathy for specificity OK? This is fine] on patient quality of life – 
the internationally acknowledged disease specific Graves’ orbitopathy Quality of Life 
questionnaire (GO-QOL) is a validated outcome for both visual function and cosmetic visual 
appearance [Au: Can you please define “appearance” here. Is this the appearance of the patient 
or the appearance of their vision changed?] 
26,27
. There is now some evidence that appearance has 
a greater negative effect on anxiety and depression than visual function
28
.  [Au: Can you please 
define “recent” by providing a timeframe?] Trials in 201829,30 used other composite primary 
outcome scores based on several factors including diplopia score, range of eye movements and 
degree of proptosis.  
 
In contrast to Clinical Activity Score, which was validated in numerous trials, the VISA score, 
although easy to document, has not been applied in prospective randomized trials up-to-now. A 
one-to-one comparison of these two assessments is worthwhile and warranted. 
 
 
 
[H1] Early identification of Graves’ orbitopathy 
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Increases in the awareness of Graves’ orbitopathy within the clinical community and earlier 
diagnosis have resulted in improvements with regards to promptness and appropriateness of 
referrals to specialist centres
31
. [Au: Edits here for clarity, please check that I have not altered 
your intended meaning. In addition, could you please be specific regarding the improvements. 
Does this mean more patients are being referred or that the patients are being triaged more 
quickly and efficaciously?Made slight change above] In response to the Amsterdam Declaration, 
the UK TEAMeD 5 approach (http://www.btf-thyroid.org/TEAMeD-5)
32
 [Au: Can you please 
add this website to the reference list? I don’t want to disrupt the formatting by doing it myself. 
The format for citing websites should be: Author. Title of online article. Website name. http 
address (2015).Added] has been developed for use by endocrinologists. This approach can be 
used to detect Graves’ orbitopathy early [Au: Changed “earlier” to “early” as “earlier” required 
a comparator this is fine] and improve outcomes for patients with Graves’ orbitopathy. 
TEAMeD’s five steps are shown in Box 2. Since >80% of cases of Graves’ orbitopathy arise at 
the same time or after the diagnosis of thyrotoxicosis
33
, targeting endocrinologists should enable 
early detection of the condition and/or institution of preventive measures in the majority of cases 
of Graves’ orbitopathy. 
 
 
[H1] Medical management of Graves’ orbitopathy [Au: I have added some more subheadings 
to this section as I feel this helps improve the flow. Please feel to remove them if you 
disagree.We agree the flow is improved]  
 
Simple medical management strategies, such as stopping smoking, use of selenium supplements 
[Au: Can you please provide a few examples here please?added] can be effective in limiting the 
disease. Restoration and maintenance of euthyroidism is essential [ in preventing disease 
occurrence and progression Au: essential for what, specifically? Disease treatment or prevention 
etc.?] as both hyperthyroidism and hypothyroidism have a negative impact on Graves’ 
orbitopathy
23
. [Au: I’ve added the following sentence to alter the narrative flow – introduce the 
simple strategies and then the more complex ones. Please feel free to alter or edit my addition if 
I have misunderstood your intended meaning slightly altered] Of the three management 
strategies for hyperthyroidism (anti-thyroid drugs, surgery and radioactive iodine)  anti-thyroid 
drugs especially and surgery do not influence the natural course of Graves’ orbitopathy (beyond 
restoration of euthyroidism), whereas radioactive iodine treatment confers an increase in risk of 
developing or exacerbating Graves’ orbitopathy; although this risk [Au: “risk” to define “this” 
OK? This is fine] can be mitigated by concomitant steroid therapy 
34
. Although not-evidence-
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based,  many clinicians who use anti-thyroid drugs opt for ‘block and replace’ therapy to optimise 
thyroid status in Graves’ orbitopathy. 
 
[H2] Smoking status [Au: I feel that this section could be improved with some guidance for 
clinicians. E.g. Do you feel clinicians should advise their patients to stop smoking and provide 
assistance for patients who do smoke? Change below]  
Clinicians should strongly encourage patients with Graves’ disease and those with Graves’ 
Orbitopathy to stop smoking. Smoking is a major risk factor for Graves’ orbitopathy since it 
contributes to both its development and progression
35,36
, and is associated with increased severity
37
. 
Furthermore, smoking negatively effects the efficacy of immunosuppressive treatments for 
Graves’ orbitopathy38,39 and smoking cessation can improve Graves’ orbitopathy outcome40. 
Smoking components might induce adipogenesis and synthesis of GAG, as suggested in an in 
vitro model of Graves’ orbitopathy; however further evidence is needed to test this hypothesis in 
vivo
41
. Smoking in patients with untreated Graves’ orbitopathy seems to be associated with an 
increase in extraocular muscle volume, but not orbital fat volume
42
. Whether vaping will have 
some degree of negative impact on Graves’ orbitopathy remains to be elucidated as nicotine 
induces release of pro-inflammatory cytokines
41
.  
 
[H2] Ocular lubricants 
Ocular lubricants and deliberate eye closure during prolonged visual tasks (such as, reading or 
use of visual display units) will alleviate symptoms and protect from corneal damage. Selenium 
supplementation (100 mcg twice a day) has been shown to be effective in stabilising mild Graves’ 
Orbitopathy during treatment as well as during a six-month follow-up
43
; [Au: effective for what, 
specifically? Added]  however we are still waiting for data on its use in Graves’ orbitopathy 
prevention. Although widely used, there is lack of evidence of benefit for using selenium 
supplementation in patients with moderate to severe Graves’ orbitopathy or inactive disease. 
 
[H2] Glucocorticoids 
Glucocorticoids are the mainstay of treatment for active disease, but there is a clear need to 
identify new therapeutic strategies. Recent randomised clinical trials indicate that intravenous 
methylprednisolone given weekly at starting doses of 0.5 g per week for six weeks then 0.25 g per 
week for another six weeks (cumulative dose of 4.5 g) seems to optimise the balance between 
efficacy and side-effects and is associated with fewer adverse events [Au: I have changed “better 
tolerated” for “adverse events” to remove the onus from patients (the idea that it is them who are 
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not tolerating a treatment) on to the treatment as it might not work for them. Edits OK? This is 
fine] than oral high dose glucocorticoids
23
. Doses higher than 4.5 g and more frequent doses than 
once a week [Au: edits here to add comparators OK? This is fine] can be used in severe or sight-
threatening disease; however, reducing relapse rates and optimising final outcomes seems to 
require combinations of current therapies, given that active disease might last 1–2 years, and 
recurrence at the time of glucocorticoids withdrawal often occurs
44-47
 (key therapeutic agents are 
summarized in Table 1). In 2018 the CIRTED (Combined Immunosuppression and 
Radiotherapy in Thyroid Eye Disease N=126) and the EUGOGO led MINGO (Mycophenolate 
in Graves’ orbitopathy for MINGO or Mycophenolate plus methylprednisolone versus 
methylprednisolone alone in active, moderate-to-severe Graves' Orbitopathy N=164)  [Au: Can 
you please define recently? changed] identified anti-proliferative treatments (azathioprine and 
mycophenolate), which have a role in improving outcomes, although mycophenolate is 
associated with markedly fewer adverse events [Au: OK? This is fine] 
29,30
. 
 
In particular, the large [Au: Can you please state the n of these trails either here or above? 
Changed above] EUGOGO led MINGO trial
30
 implies the potential advantage of combining IV 
steroids to a non-steroidal anti-proliferative drug pertaining to better and sustained response. The 
findings were confirmed by a large (N=174) [Au: Could you please define the n for this trial? 
added] randomised trial from China which also reported the beneficial effect of mycophenolate
48
. 
However, in both studies
30,48
 [Au: of which study, specifically? Both studies – text changed]  the 
drug had no clinically relevant effects on proptosis [G] [Au: I have highlighted suggestions for 
glossary terms throughout your manuscript with a [G]. Please provide succinct, one-sentence 
definitions for these specialist terms in the space provided at the end of the document. Added] 
and/or diplopia [G done]. Further, rehabilitative surgery was often required after the immune-
suppressive therapy was stopped.  
 
With regards to the CIRTED trial
29
, although post-hoc analysis showed a potential beneficial 
effect of combining steroids and azathioprine drawing definitive conclusions is limited by the 
high number [Au: what proportion of participants dropped out? Text added] of dropouts. 
Although 103 of the 126 trial participants (81.2%) provided outcome data, 84 (66.6%) completed 
their allocated treatment of radiotherapy or sham radiotherapy and  only 57 (45.2%) continued 
to take azathioprine or placebo up to 48 weeks  (therefore dropouts had less [Au: less than what? 
This statement requires a comparator] effect on radiotherapy than azathioprine as most had 
received radiotherapy prior to withdrawal). Studies from the 1980’s [Au: Could you please define 
10 
 
older by providing a timeframe?] suggested similar benefits to azathioprine might be observed 
with cyclosporin
49
, and cyclosporin has subsequently been widely used for moderate to severe 
disease. Current guidance for the initial management of Graves’ orbitopathy is summarized in 
Figure 1
23,50
. 
 
The aim of treatment of Graves’ orbitopathy (Box 3) is to suppress orbital inflammation and 
reduce consequent tissue re-modelling in extraocular muscles, orbital fat and other periocular 
soft tissues
51,52
. Traditionally, glucocorticoids have been the treatment of choice for active disease. 
Methylprednisolone inhibits key pathological factors including prostaglandin secretion, fibroblast 
activity, GAG production
53
, as well as the expression of pro-inflammatory proteins in the orbital 
tissue as shown in a proteomics study
54
. Furthermore, high dose methylprednisolone reduces the 
number of circulating dendritic cells and decreases TSHR-Ab levels
45
, which have a key role in 
driving the activity and severity of Graves’ orbitopathy.  
 
 
The use of local, low dose (10 Gy) [Au: Could you please define “low dose” by providing a 
figure? done], orbital radiotherapy in Graves’ orbitopathy yields less irradiation-induced short 
and long-term side-effects
55
 although remains controversial. In randomized trials that include 
patients with mild or moderate-to-severe Graves’ orbitopathy 56,57, radiotherapy as a single agent 
was equivalent to oral prednisolone
57
 and significantly (p=0.02) [Au: Can you please provide a P 
value for the use of “significantly” here? If not, we prefer the use of “markedly”, “notably” etc. 
changed] better than sham irradiation
56
. Furthermore a randomized trial of low dose (10 Gy) 
versus high dose (20 Gy) in moderate to severe Graves’ Orbitopathy showed low dose 
radiotherapy was at least as effective and much better tolerated than high dose treatment
55,58
. In 
this three arm study protracted low dose therapy for 20 weeks was the preferred treatment by 
patients
57
.   
  
  
However a [Au: Can you please define the use of “recent” here by proving a timeframe? 
changed] trial in 2001 showed less clear benefit from radiotherapy and produced conflicting 
results, possibly due to treatment of disease that was beyond the active phase or the non-
randomised or masked study design
59
. The CIRTED study made particular effort to focus on 
participants with active disease, including a two week trial of steroid response, and showed no 
additional benefit when orbital radiotherapy was added to high dose oral glucocorticoids
29
.  
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To date, no randomized trials of radiotherapy plus intravenous glucocorticoids as the standard 
regimen have been reported
29,59
. However, as shown in the Mourits double-blind trial
60
 and in 
several other randomized trials
56,57
 and recommended in the ETA guidelines
23
 radiotherapy is 
likely to have a role in patients with diplopia and motility disturbances . In a 2018 [Au: Can you 
please define “recent” here? changed] review61, it was proposed that orbital radiotherapy might 
help potentiate the mechanism of high doses of steroids leading to inactivation of the disease. 
However, the lack of additional efficacy with high dose oral steroids in the CIRTED trial
29
 
suggests that radiotherapy should not routinely be used in combination with high dose steroids. 
It should be noted that CIRTED did not address the benefit of radiotherapy alone in patients 
with active/severe eye disease and disturbances of muscle motility and/or diplopia as 
recommended in previous guidelines
25
. The CIRTED study also did not directly answer the 
question of whether radiotherapy confers additional benefit to patients receiving pulsed 
intravenous steroid, although this would seem unlikely given the lack of additional benefit with 
the lesser amount of steroid administered during oral dosing in CIRTED.     
 
 
 
[H2] Surgical management of Graves’ orbitopathy 
Despite medical advances, surgery has an important role in the treatment of Graves’ orbitopathy. 
Surgery is required in the acute phase of the disease where there is immediate risk to vision (optic 
neuropathy). The optic nerve is vulnerable to compression and vascular compromise as it enters 
the orbit, where it is crowded by the origins of the surrounding extraocular muscles. Compression 
of the optic nerve [Au: This needs to be followed by a noun, could you please define “this” here? 
changed] occurs in 3–5% of patients62 and cases where optic neuropathy is not responding to 
alternate high doses (750 mg/day 3 days per week) of intravenous steroids for two consecutive 
weeks will require orbital decompression
23
. The majority of surgery is rehabilitative (Box 4). 
[H1] Mechanistic insights from recent clinical trials. 
The key clinical trials are summarized in Table 1, which highlights the variable effect of altering 
different pathways in the pathogenesis of Graves’ orbitopathy. These pathways are summarized 
in Figure 2. A summary of the doses and monitoring requirements for agents utilised in Graves’ 
orbitopathy since 2015 [Au: “Newer” required a comparator. Could you please provide a date 
here instead? changed] is shown in Table 2.  
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[H2] Mycophenolate 
Mycophenolate mofetil (MMF) is used in combination with glucocorticoids to prevent allograft 
rejection
63
. MMF substantially inhibits proliferative responses of T-lymphocytes and B-
lymphocytes to both mitogenic and allospecific stimulation and antibody formation by B-
lymphocytes
64
. Furthermore, it prevents the glycosylation of lymphocyte and monocyte 
glycoproteins that are involved in intercellular adhesion to endothelial cells and inhibits 
recruitment of leukocytes into sites of inflammation
65,66
. [Au: Please reference this 
statement.done] MMF also potentially modulates the chemotaxis of infiltrating activated 
lymphocytes in inflammatory tissue
66
; however, [Au: could you please define “recent” here by 
providing a timeframe? changed] data from 2019 also indicate that MMF can act at the level of 
the phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) pathways in 
non-lymphoid cells, offering a mechanism of direct effect on orbital fibroblasts
67
 (Figure 2).  
 
In 2017, and 2018 [Au: Could you please define the use of “recent” here by providing a 
timeframe? changed] two studies [Au: Could you please provide the n for each of these 
studies?already done earlier it’s the MINGO and YE study] prospectively and randomly tested 
mycophenolate versus steroid
30,48
. In the 2017 Chinese study
48
 (in which the authors tested [Au: 
OK? This is fine] MMF) improvements were reported in Clinical Activity Score, [Au: OK? This 
is fine] diplopia and proptosis, although this was not observer masked [G: [Au: Could you please 
define “observer masked” here? Thought best to add to glossary].  
 
The observer-masked European study
30
 [Au: Could you please provide the n number here? 
Mingo study again] (in which the authors investigated [Au: OK? This is fine] Mycophenolate 
sodium) revealed additional benefits of mycophenolate. This trial
30
 showed in a post-hoc analysis 
a better outcome in terms of overall ocular improvement at week 24 (end of intervention) and 
week 36 (three-month follow-up) in the group receiving combination therapy compared with the 
group that were treated by intravenous glucocorticoids alone. However, the authors also reported 
that relapses occurred in both groups at the same extent. Additional benefits were noted in the 
combined treatment group (steroids + mycophenolate sodium), in detail  better results were 
observed in the combined treatment group  pertaining to overall ophthalmic improvement at 
weeks 24 (p=0.03) and 36 (p=0.02), CAS at week 12 (p=0.04), downgaze duction (eye muscle 
motility when looking downgaze) at week 36 (p=0.009), eyelid swelling (week 36, p=0.027) and 
caruncle swelling (week 36, p=0.030). [Au: Could you please detail these benefits? changed] [Au: 
Could you please explain what downgaze duction and elevation are? Changed also] ,  
13 
 
 
[H2] Azathioprine  
Azathioprine is an anti-proliferative agent with similar mode of action to mycophenolate. 
Although ineffective as monotherapy to treat Graves’ orbitopathy 68, it could be a potential adjunct 
to steroid treatment
29
, and like MMF, potentially could act directly on signalling pathways in the 
pre-adipocyte. Data from the CIRTED trial
29
 identified potential benefits with regard to reduced 
relapse in features of Graves’ Orbitopathy [Au: were these Graves’ orbitopathy relapse rates? 
Can you please specify changed] after withdrawal of steroid although it is less well tolerated than 
MMF
29
. It is important to note that in the CIRTED trial 66% of participants were allocated to 
azathioprine and 45% of those allocated to placebo did not complete 48 weeks of treatment
30
. 
However, the majority of patients did return for review (82%), which strengthens the validity of 
the study, with no baseline bias in the returners between groups.  
 
Despite low adherence rates, even in intention to treat, the point estimate for odds ratio for 
improvement for patients treated with azathioprine [Au: Addition for clarity OK? This is fine ] 
was substantial - 2.56 (95% CI 0.98–6.66, p=0.054). In a sensitivity analysis in which patients who 
withdrew during the trial were recoded to unfavourable outcomes regardless of their status at 48 
weeks, the effect of azathioprine treatment was enhanced (OR 3.65, 95% CI 1·34–9·86, p=0.011). 
Furthermore, in a post-hoc analysis of patients who completed their allocated therapy the OR 
for improvement was very large; 6.83 (1.66–28.1, p=0.008). No significant improvement was 
observed in GO-QoL compared to placebo — the major benefit appeared to be in reducing the 
relapse rate after steroid withdrawal. These findings are therefore consistent with a role for 
azathioprine as a steroid sparing agent. As the CIRTED trial
29
 used oral rather than intravenous 
glucocorticoids, conclusions can also not be drawn on the role of azathioprine and intravenous 
glucocorticoids. Taken together, the data suggest MMF should be the preferred anti-proliferative 
agent in Graves’ orbitopathy based on tolerability and probable efficacy. 
 
[H2] Teprotumumab  
Teprotumumab is a recombinant, fully human monoclonal antibody of the immunoglobulin G1 
(IgG1) subclass. This monoclonal antibody binds to the insulin-like growth factor 1 receptor 
(IGF-1R) with high affinity, behaving as a pharmacological, functional inhibitor, blocking the 
activation of IGF-1R by its endogenous ligands (IGF-1 and insulin-like growth factor 2, IGF-2) 
and causing internalization of the receptor
69,70
. Teprotumumab, results in a complete shutdown 
of IGF-1R signaling and importantly shows no functional agonistic activity.  
14 
 
 
This blocking of the IGF-1R was predicted to have substantial benefits in Graves’ orbitopathy as 
active (inflammatory). Graves’ orbitopathy has been reported to be triggered and driven by 
autoimmune activation of orbital fibroblasts by autoantibodies with receptor agonist properties 
that signal through IGF-1R-dependent mechanisms
71
 (Figure 2; discussed in more detail later in 
the review). In particular, the activation of orbital fibroblasts by autoantibodies stimulates the 
release of chemoattractant cytokines, promoting T-cell infiltration into orbital tissues
72
. This 
infiltration [Au: addition of “infiltration” OK? Please feel free to edit my changes if I have 
misunderstood you this is fine] triggers a local inflammatory response which, combined with the 
autoimmune driver, results in proliferation and differentiation of fibroblasts, tissue expansion, 
increases in extracellular matrix, edema and extensive remodeling of orbital tissues (Figure 2)
70,71,73
. 
Teprotumumab will therefore fully block these pathophysiological responses. In keeping with 
this, the main impact of teprotumumab on Graves’ orbitopathy seems to be in markedly reducing 
proptosis and clinical activity score, including improvements in double vision
73
. The initial 
impressive results with teprotumumab, which is not yet approved by regulatory authorities, may 
well be a ‘game-changer’ but need to be replicated in future studies and compared with 
intravenous glucocorticoids.  
 
[H2] Rituximab  
 
Rituximab is a monoclonal antibody that targets CD20, which is only expressed by B cells, and 
is present from the stage of pre-B cells to mature and memory B cells, but not on the plasma 
cells that ultimately produce antibodies
74
. [Au: Please reference this statement. done] In 2015 
[Au: Can you please define recent here by providing a timeframe? Have modified the sentence] 
2 clinical trials
75,76
 reported contradictory outcomes; no benefit in 1 trial when  compared with 
placebo
75
 however significant (P=0.006) [Au: Can you please provide a P value to go with your 
use of “significant” here? added] improvement in clinical activity score compared with IV 
steroids
76
. A reanalysis of the data implied that rituximab is most effective when administered 
early to patients with active disease
77
. Although rituximab depletes B cells, it does not necessarily 
reduce TSHR-Ab levels, suggesting other modes of action, for example such as a reduction in 
antigen presentation and activation of T cells
78
. More data and larger randomized trials are 
warranted prior to a definitive recommendation of the drug in patients with active and severe 
Graves’ Orbitopathy.  
 
[H2] Tocilizumab 
15 
 
 
A preliminary study reported that tocilizumab, a humanized monoclonal antibody against the 
interleukin-6 receptor, showed efficacy in terms of activity reduction when used off-label in 
Graves’ orbitopathy refractory to intravenous [Au: OK? This is fine] glucocorticoids79. In 
addition, a subsequent case report that included two patients confirmed efficacy [Au: Was this 
efficacy confirmed in the same terms? That is in terms of activity reduction when used off label? 
yes]
80
.  
 
More recently in 2018, [Au: Could you please provide a timeframe here? done] a multi-centre 
randomised double masked trial in Spain identified that the use of tocilizumab in glucocorticoid 
resistant Graves’ orbitopathy resulted in an almost [Au: For the next points, “higher” odd, 
“greater chance” and “greater improvement” could you please specify what tocilizumab was 
compared with in the trial?added] 10-fold higher odds of having a reduction in clinical activity 
score of at least 2 points, a greater chance of having a clinical activity score less than 3, greater 
improvement in EUGOGO ophthalmic score and a reduction of exophthalmos than placebo
81
. 
These impressive initial findings need confirmation in a larger clinical trial as concerns have been 
raised from this study due to the small numbers of patients included (N=32), [Au: How many 
patients were included in the study?added] who were also heterogeneous with regard to their 
Graves’ Orbitopathy [Au: TED used here, is my definition OK? Fine but Graves’ Orbitopathy 
also fine] severity, pre-treatment with a variety of immunosuppressive drugs and not all the 
required ophthalmic data were clearly stated
81
.  
 
[H2] Other novel targeted therapies 
 
Belimumab has been used off-label for Graves’ orbitopathy, but well-designed focused 
randomized controlled trials are needed before drawing any definitive conclusion about its 
efficacy at treating the disease [Au:OK? This is fine]
51
. Belimumab is a monoclonal antibody 
directed towards the B cell activating factor, and similar to rituximab, belimumab targets B cells, 
especially naïve and transitional B cells. It is currently licensed for systemic lupus erythematosus 
[Au: Definition of SLE OK? This is fine] 
82
 and clinical trials in Graves’ orbitopathy are currently 
ongoing
51
.  
 
Alternative non-immune therapies have been considered for the treatment of Graves’ 
orbitopathy. Bimatoprost, a treatment for glaucoma, has been reported to cause enophthalmos 
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and laboratory evidence suggests it inhibits proliferation and differentiation of orbital fat cell 
precursors
83
. Although a 2019 [Au: Could you please define “recent” here by providing a time 
frame?altered] clinical trial in stable, late, inactive Graves’ orbitopathy revealed no evidence of 
benefit
84
, trials in early, active disease are warranted.  
 
[H1] Pathogenesis of Graves’ orbitopathy [Au: as level 1 (H1) headings can only have a 
maximum of 38 characters, including spaces, I have edited this heading. Changes OK?]  
 
[H2] New insights on pathogenesis [Au: I have added this new subheading here as I feel that the 
sections below fit well into a section on pathogenesis. What do you think? Please feel free to edit 
my changes if you disagree.]  
The focus of studies into the pathogenesis of Graves’ Orbitopathy[Au: Which studies 
specifically? Into the pathogenesis of Graves’ orbitopathy?changed] has been largely on the 
orbital fibroblast as these are key in the early pathogenesis of Graves’ orbitopathy.[Au: Could 
you please define recent here by providing a time frame? added] Studies reported in 2015 have 
indicated the mesenchymal-stem cell (MSC) properties of orbital fibroblast, using both in vitro 
lineage specific differentiation protocols and phenotyping by flow cytometry. Notably orbital 
fibroblasts are able to undergo adipogenesis, which probably predominates in the manifestation 
of Graves’ orbitopathy. They can also undergo chondrogenesis and myogenesis, indicating their 
pluripotency
85,86
. In addition, Sven Brandau [Au: Could you please use first names on first 
mention?added] and colleagues demonstrated osteogenesis and neurogenesis in orbital 
fibroblast and orbital mesenchymal stem cells from patients with Graves’ orbitopathy86, [Au: Edits 
for clarity here OK? This is fine] [Au: Please reference this statement added.] although non-
Graves’ orbitopathy tissues were not analysed so it is unclear whether this is a truly disease-
specific feature.  
 
[Au: For the pathogenesis section, I it might be worth briefly explaining the role of adipogenesis 
again Added sentence] Adipogenesis, which is the differentiation process by which precursor 
cells develop into mature fat cells, has been demonstrated using ex vivo samples from patients 
with Graves’ orbitopathy87 . However, we are unaware of similar studies investigating 
chondrogenesis and myogenesis, which might also contribute to orbital expansion. [Au: OK this 
is fine?] Myogenesis might be relevant to studies reporting increased muscle volume early in 
disease and its correlation with Graves’ orbitopathy severity, whereas orbital fat volume expanded 
later in disease and correlated with proptosis
88
. 
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 Analysis by flow cytometry has shown that orbital fibroblasts are largely positive for CD90 (Thy-
1) and negative for CD45
85,86
, [Au: Please reference this statement.done] which are positive and 
negative markers of mesenchymal stem cells [Au: OK? This is fine] , respectively
89
. [Au: Please 
reference this statement.done] Orbital fibroblasts are also particularly susceptible to 
inflammatory stimuli, compared with fibroblasts elsewhere. For instance, their upregulation of 
CD40 makes them targets for activation by CD40L on T lymphocytes
89
. [Au: Please reference 
this statement. done] Furthermore, TSHR-expressing T cells, which could be activated by 
TSHR-Ab, might further stimulate adipogenesis of orbital fibroblasts in Graves’ orbitopathy 
through a PPARg ligand produced via upregulated cyclo-oxygenase
90
 (Figure 2). There is 
potential for strategies that use the suppressive function of regulatory T cells to also prove 
beneficial to patients with Graves’ orbitopathy 91. 
 
Apart from orbital fibroblasts, fibrocytes, which are CD34
+
 bone marrow-derived progenitor 
cells, migrate from the circulation into sites of inflammation and injury (Figure 2). They have 
been identified in the orbit, particularly those of patients with Graves’ orbitopathy,92,93 and 
reported to express two of the major thyroid autoantigens, the TSHR and thyroglobulin
94
. Studies 
of immune cells in the orbit have been hampered by the paucity of suitable material, but a review 
of available studies indicated that both CD4+ and CD8+ T cells, as well as B cells, were present 
in the majority of orbits examined and a 2018 [Au: Could you please define recent here by 
providing a timeframe?added] report suggested that the level of infiltration correlates with disease 
activity
95
. Macrophages are found in the orbits [Au: found in the orbits? Can you please specify 
done] in early disease
96
, whilst monocytes and mast cells have also been identified and associated 
with secretion of platelet-derived growth factor (PDGF), which stimulates orbital fibroblasts 
proliferation and hyaluronic acid (HA) production, especially the PDGF-BB isoform, in both 
Graves’ orbitopathy and non-Graves’ orbitopathy orbital fibroblasts97. Mast cells also produce 
prostaglandins which are able to enhance adipogenesis
98
. Overall, it is increasingly recognised that 
there are multiple overlapping factors in the development of Graves’ orbitopathy, which suggest 
a combination of treatments might be required.  
 
[H2] Cellular mechanisms [Au: Edits to shorten heading so that it fits within our limits OK? In 
addition, I feel that this section works as a subsection within the pathogenesis section. Do you 
agree? If not, please feel free to edit my changes This is fine]  
While the role of TSHR as a Graves’ orbitopathy autoantigen is widely accepted, whether the 
IGF-1R
69,99,100
 is also a target of the autoimmune response remains controversial. Of note, however, 
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both TSHR and IGF-1R are expressed in orbital tissues and their expression is increased in 
patients with Graves’ orbitopathy72,87. [Au: could you please reference this statement?] Since 2013 
the [Au: Could you please define recent by providing a timeframe? added] establishment and 
replication in two laboratories of an animal model of Graves’ orbitopathy, which is induced by 
immunisation with TSHR alone, supports the view that the TSHR is the target of orbital 
autoimmunity in Graves’ orbitopathy101,102.  
 
The expression of TSHR in orbital fat was inferred by Antonio Feliciello [Au: Could you please 
include first names on first use? added] and colleagues 
103
 but confirmed using northern blot by 
Michele Crisp [Au: [Au: Could you please include first names on first use? added] and 
colleagues
104
. Immunohistochemical analysis of orbits revealed TSHR immunoreactivity, using 
three different monoclonal antibodies
105
 . TSHR [Au: OK? This is fine] was detected in 0/20 
strabismus samples, but in all 30 muscle biopsies from patients with Graves’ orbitopathy, where 
they were associated with spindle-like cells between the extra ocular muscles; abundant mast cells 
were also present
106
. Several studies have illustrated that TSHR activation can impact 
adipogenesis; gain-of-function TSHR mutants introduced into orbital fibroblasts demonstrated 
that early stages of adipogenesis were enhanced
107
. Using cultured mouse embryonic stem cells, 
Min Lu [Au: Could you please include first name on first use? added] and colleagues showed 
that TSH can stimulate adipogenesis, even in the absence of adipogenic factors, suggesting that 
TSHR activation can initiate the early lineage commitment process
108
. In another study, Rebecca 
Bahn [Au: Could you please include first name on first use? added] and colleagues reported that 
M22, a human monoclonal TSAb, can substitute for insulin in an adipogenic cocktail
109
. 
However, the fact that the patient from whom M22 was derived did not have Graves’ orbitopathy, 
and has not since developed the condition, must question how relevant it is to orbital remodelling 
processes. 
  
Hyaluronan [Au: Could you please define HA here and throughout?added ] is generated by 3 
synthase enzymes (HAS1, HAS2 and HAS3). TSHR activation of orbital fibroblasts, by 
signalling through cyclic AMP (cAMP) – protein kinase A (PKA) to cAMP response element-
binding protein (CREB) binding sites in the promoters of HAS1 and HAS2, increases HA 
production
110
. Furthermore, similar effects were obtained using a TSHR antibody devoid of 
TSAb activity, so-called neutral TSHR-Ab
110,111
. 
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Lei Zhang [Au: Could you please include first name on first use?added] and colleagues also 
demonstrated that the processes of adipogenesis and hyaluronan production were linked in 
orbital adipose tissue, where hyaluronan accumulation increases during adipogenesis, but not in 
fat from other depots
112
. [Au: Edits to the following sentence for narrative flow OK? This is fine] 
The link between the pathogenesis of Graves’ orbitopathy, hyaluronan production and 
adipogenesis was revealed in fibroblasts from orbital adipose tissue (OAT), but remarkably, was not 
observed in white adipose tissues (WAT), where adipogenesis leads to Hyaluronan reduction
112
. 
Human OAT is a neural crest derived fat depot within the orbit
113
, while WAT is from mesodermal 
origin
114
. [Au: Please reference this statement. done] It is also interesting to note that while OAT 
is expanded in patients with Graves’ orbitopathy, WAT shrinks due to hyperthyroidism115. [Au: 
Please reference this statement.done] Unlike WAT, OAT seems to not be a storage site for 
calories, and this observation is consistent with the observation that the worldwide increasing 
prevalence of obesity has not been associated with reports of OAT expansion
116,117
.  
 
Taken together these findings suggest a very different mechanism in OAT expansion and 
underlying orbital fibrosis adipogenesis. Indeed, there is a specific cell-signaling network presenting 
in fibroblasts from OAT distinct from that in WAT
112
. In particular mTORC1 negative-feedback in 
IGF1-PI3K-Protein kinase B (Akt) signaling is absent in OAT-orbital fibroblasts, but present in 
WAT 
112
. Studies have also shown TSHR–PKA, IGF1R–PI3K–Akt and mTORC1 signalling 
worked together in the pathogenesis of Graves’ orbitopathy 99,109,110,118-120.  
 
Whilst data are strong for the effect of TSHR in Graves’ orbitopathy, IGF-1R is also likely to have 
a key role in the disease. [Au: I have made some edits to this sentence to improve the narrative 
flow. Please check that I have not altered your intended meaning and feel free to alter my changes 
if you think I have. This is fine] This hypothesis [Au: OK? This is fine] is exemplified by the 
2017 trial which [Au: Can you please define recently here by providing a timeframe?added] 
reported dramatic reduction in proptosis in patients with Graves’ orbitopathy who had been 
treated with Teprotumumab
73
, which suggests a central role for signalling via IGF-1R in Graves’ 
orbitopathy pathogenesis. This finding has been further illustrated [Au: Edit OK? This is fine] 
by studies that have highlighted the importance of downstream factors of IGF1–PI3K signalling and 
revealed that nuclear Forkhead transcriptional factors, FOXOs, serve as convergence points for 
TSHR and IGF-1R signalling pathways in Graves’ orbitopathy121,122. Specifically, FOXO1 and 
FOXO3a served as repressors, which protect orbital fibroblasts from excessive adipogenesis and 
marked over-production of HA, respectively
121
. In addition, an old drug, trifluoperazine 
20 
 
hydrochloride, which enhances FOXO repressors abolished adipogenesis and HA production in 
OAT-orbital fibroblasts
121
. Unfortunately this drug has substantial adverse effects including liver 
damage, bradycardia and dyskinesia [Au: Could you please provide one or two examples? done] 
and therefore has no role in thyroid eye disease
123
. Alternative drugs targeting FOXO transcription 
factors  [Au: What is “this” referring to here specifically?changed] might therefore replicate the 
recent clinical trial with teprotumumab showing reduced proptosis of severe Graves’ orbitopathy 
patients by inhibiting IGF-1R signalling
73
 (Figure 2). Taken together, FOXOs could be an 
alternative non-immunosuppressive therapeutic target that would potentially reset tissue 
remodelling and pathological orbital expansion in Graves’ orbitopathy with less cost than 
teprotumumab. Furthermore, they may have wider effects on Graves’ orbitopathy pathology. 
 
[H1] Two autoantigens, possible cross-talk?  
Patients with severe Graves’ orbitopathy have an increased risk of relapsing hyperthyroidism and 
are unlikely to remain in remission
124
. Although several authors have reported correlations 
between TSAb titre and Graves’ orbitopathy prevalence and/or severity125-127, the fact that not all 
patients with Graves’ orbitopathy have TSHR-Abs with stimulating activity on the TSHR 
(TSHRAbs [Au: OK? This is fine] activate PKA–cAMP cascade) has led to two differing 
conclusions. The first is that TSHR-Abs signal might exist that signal to other cascades that might 
exist and the second that there is an additional autoantigen
111,128
. [Au: Is this what you mean? 
Please edit my changes if I have misunderstood you modified edit slightly]  
 
IGF1R has been the focus of considerable attention following the early demonstration that IgGs 
in patients with Graves’ orbitopathy are able to inhibit binding of IGF1 and therefore is analogous 
to TSH-binding inhibitor immunoglobulin (TBII) in the thyroid
100
. Terry Smith [Au: Could you 
please use first name on first use? added] and colleagues have reported Graves’ orbitopathy IgGs 
with a wide range of IGF1R ‘stimulating’ activities (via IGF-1R auto phosphorylation), from 
enhanced orbital fibroblasts proliferation to increased secretion of inflammatory cytokines and 
elevated production of GAGs
69,70
. However, reports from other authors have failed to 
demonstrate that; autoantibodies are able to auto-phosphorylate the IGF-1R; that IGF-1R 
autoantibodies simply binding the receptor are more abundant in patients Graves’ orbitopathy 
than in healthy controls
,129,130
; or that autoantibodies are more prevalent in patients with Graves’ 
disease [Au: OK?this is fine] with Graves’ orbitopathy than free of eye disease130.  
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An alternative to direct activation of the IGF-1R, inducing Graves’ orbitopathy is the possibility 
of a synergistic effect of IGF-1R and TSHR. Christine Krieger [Au: Could you please include 
first name on first use?added] and colleagues
120
 described synergistic actions of TSH and IGF-1 
in stimulating HA, although the cells were in a semi-adipogenic medium likely to increase TSHR 
expression. The group also explored the biphasic dose-response of M22 (a human [Au: OK? 
This is fine] monoclonal TSHR-Ab with stimulating activity that does not induce IGF-1R 
autophosphorylation) and found that even though a TSHR antagonist inhibited both phases, an 
IGF-1R antagonist inhibited only the higher potency phase, leading to their notion of cross-talk. 
In subsequent studies the group proposed combination therapy using low dose TSHR and IGF-
1R antagonists as IGF-1R antagonism alone (as in Smith and colleagues teprotumumab trial)
73
 
might not benefit patients with Graves’ orbitopathy who have high TSAb levels. One could 
therefore envisage alternative signalling cascades to explain the TSHR–IGF-1R cross-talk (Figure 
2), but another explanation is that activation of IGF1R by IGF1 (increased in Graves’ disease and 
Graves’ orbitopathy) is able to upregulate TSHR expression – as has been reported in the thyroid 
70
. 
 
[H2] IL17 and a possible role for the microbiome [Au: I believe that this section fits within the 
pathogenesis section still. Please feel to make this a Level 1 (H1) heading if you disagree this is 
fine]  
One of the major problems facing patients with [Au: Edit OK? This is fine] Graves’ orbitopathy 
is fibrosis, which results in permanent remodelling of the orbit. Fibrosis follows myofibroblast 
differentiation of CD90–Thy-1 positive orbital fibroblasts, which are stimulated by transforming 
growth factor (TGF)-beta. In 2016 [Au: Could you please define “recently” here by providing a 
timeframe? added] a role for Th17 cells has been implicated in fibrosis, in line with other 
autoimmune conditions in which Th17 cells have been found in autoimmune lesions, such as 
multiple sclerosis’ plaques. Bin Li [Au: Could you please use first name on first mention? Bin 
Li is full name] and colleagues work
131
 showed a significantly (p<0.01) higher proportion of IL-
17A-producing T cells in patients with Graves’ orbitopathy compared with healthy controls  [Au: 
Compared with who? In addition, can you please include a P value for the use of “significantly” 
here? added] and the recruitment of both CD4 and CD8 T cells in Graves’ orbitopathy orbits. 
In addition, orbital tissues from patients with Graves’ orbitopathy expressed more IL-17A 
receptor, IL-17A, and its related cytokines (Figure 2), and the authors noted severe fibrotic 
change compared with normal controls
132
. A product isolated from traditional Chinese medicine 
(vialinin A) was able to inhibit RORγt, a transcription factor which drives Th17 differentiation 
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and thus reduce  [Au: The numbers of what, specifically?changed] numbers of TH17 cells
131
. 
This finding might lead to additional therapies to limit the disfigurement observed in Graves’ 
orbitopathy. 
 
[H1] Animal models of Graves’ orbitopathy 
 
Whilst considerable progress has been made in understanding the pathogenetic mechanisms 
operating at the end stages of disease, relatively little is known about the factors that cause loss of 
immune tolerance and trigger disease onset. Animal models can be invaluable in this context and 
numerous attempts have been made to develop a robust model of induced Graves’ orbitopathy 
in mice. [Au: Edit to the following sentence OK? Minor changes] Many of these models, 
however, were only able to induce Graves’ disease, with no signs of Graves’ orbitopathy133-135. In 
one instance researchers developed a BALB/c based mouse model that had some aspects of 
Graves’ orbitopathy 136, but this was not reproducible in different centres, which suggests a role 
for environmental variables, including micro-organisms, interfering with Graves’ orbitopathy 
pathogenesis
137
.  
 
Since 2011 [Au: Could you please define “recently” by providing a timeframe?added] , success 
has been achieved using an expression plasmid for the TSHR-A subunit that was introduced 
using electroporation in female BALB/c mice
101,102,138
. A notable proportion of the mice developed 
a Graves’ orbitopathy-like disease, with evidence of fibrosis138, inflammation101 and enhanced 
adipogenesis
101,102
. Considering the previous challenges in reproducing Graves’ orbitopathy animal 
models in different environments 
137
 this model has been reproduced in parallel in two 
independent laboratories (UK and Germany), following the same immunisation procedure
102
. 
This finding provides strong evidence for the TSH-receptor being a target autoantigen in the 
Graves’ orbitopathy. Interestingly, however, while the induced Graves’ orbitopathy mice had 
similar features in both centres (enhanced adipogenesis and atrophy of ocular muscles), there 
were some differences, with a marked proportion of mice in centre 1 (UK) developing 
hyperthyroidism, while all mice in centre 2 (Germany) remained euthyroid
102
. [Au: Please 
reference this statement. added] Some of the discrepancies could be attributed to differences in 
gut microbiota composition across the two centres, as shown in a subsequent study evaluating 
disease-associated microbial taxonomies
139
. [Au: Please reference this statement.added]  
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For example, marked differences in α-diversity, β-diversity and in the taxonomic profiles were 
observed between TSHR-immunized mice in the two centres (for example the genus 
Lactobacillus was more abundant in Germany, while Bacteroides and Bifidobacterium counts 
were more abundant in UK). The gut microbiota was also compared in TSHR and βgal 
untreated control mice in Germany where the authors noted a shift in the TSHR immunized 
mice bacterial communities (β-diversity weighted Unifrac) together with a significant (p<0.005) 
[Au: could you please provide a P value for the use of significant here?added] positive correlation 
between the Firmicutes phylum counts and orbital-adipogenesis
139
. This interplay between gut 
microbiota and disease progression might reveal additional novel insights into the 
pathophysiology of Graves’ orbitopathy.  
 
 
[H1] Conclusion 
 
Developments in our understanding of the pathogenesis and natural history of Graves’ 
orbitopathy over the past five years [Au: addition of 5 years to provide timeframe OK? This is 
fine] have led to renewed focus on how to optimise management of Graves’ orbitopathy. It is 
increasingly clear that early interventions are likely to substantially alter the course of the disease 
and improve long term outcomes and associated morbidity. Furthermore, with the identification 
of multiple therapeutic targets (Figure 2; table 3), the synergistic potential of combination therapy 
has emerged. However, confirmatory trials are still warranted and require a comparison with 
current Graves’ orbitopathy therapy for moderate to severe disease. If confirmed this finding will 
open the door to a new era of agents that are either non-immunosuppressive or have very 
selective effects on the immune system. Of particular importance for current patients, however, 
is that we are yet to identify a non-surgical intervention that can improve outcomes in the ‘burnt-
out’ phase140. Future trials should also evaluate outcomes beyond one year, to confirm that early 
intervention reduces long term orbital deformity and the need for rehabilitative surgery and 
improve long term quality-of-life. 
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Box 1 Key validated Graves’ orbitopathy activity and severity scores 
 
Scores Assessing Disease Activity 
• Clinical Activity Score — based on pain, redness, and swelling swelling.The baseline 
CAS assessment is scored out of 7. Repeat clinical activity score assessments are scored out of 
10 points as this includes changes in proptosis, eye movement and visual acuity
19
. [Au: Please 
reference this statement.done]  
 
• VISA-I — Inflammation component based on caruncular oedema, chemosis, 
conjunctival redness, lid redness, lid oedema and retrobulbar ache
18
 [Au: Please reference this 
statement added. Could you please also explain what is meant by caruncular (G), chemosis (G) 
and retrobulbar(G) for our non-specialist readers? Added to glossary]  
 
Objective Scores Assessing Graves’ orbitopathy Severity 
 
• EUGOGO — based on whether sight-threatening Graves’ orbitopathy (requiring 
immediate intervention (dysthyroid optic neuropathy and/or corneal breakdown), moderate-to-
severe Graves’ orbitopathy (requiring immunosuppression if active or surgical intervention if 
inactive patients usually have one or more of lid retraction > 2mm, moderate or severe soft tissue 
involvement, exophthalmos > 3mm constant or inconstant diplopia) or mild Graves’ orbitopathy 
where it is difficult to justify immunosuppressive or surgical therapy (minor lid retraction <2 mm, 
mild soft tissue involvement, exophthalmos <3 mm, transient or no diplopia, and corneal 
exposure responsive to lubricants) 
23
 [Au: Please reference this statement. Done]  
 
• VISA–VSA vision, strabismus, and appearance components. Vision is assessed by acuity, 
colour vision and fields. Strabismus is assessed by diplopia and motility restriction and 
appearance is assessed by appearance concerns and evidence of ocular exposure
8
. [Au: Please 
reference this statement.done]  
 
 
• Ophthalmopathy Index – a 25 point score covering soft tissue inflammation, 
exophthalmos, palpebral aperture, diplopia, corneal involvement and evidence of optic 
neuropathy
22
. [Au: Please reference this statement. done]  
 
• NOSPECS — a mnemonic acronym for ‘no symptoms and/or signs, only signs, soft tissue 
involvement, proptosis, extraocular muscle involvement, corneal involvement, sight loss
20,21
 [Au: 
Please reference this statement.done]  
 
• Graves Ophthalmopathy Quality of Life (GOQOL), introduced by EUGOGO,  is a 
disease specific quality of life score focussing on visual function and cosmetic visual 
appearance26-28. 
  
 [Au: Does this mean there aren’t any official scores? If so, I would suggest removing this heading 
agreed added GOQOL and removed modified the section  
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Box 2: TEAMeD 5 Step approach
32
 [Au: Please reference this statement. done]  
 
• Diagnose Graves’ disease accurately (measure TSHR-Ab) 
• Screen all patients with Graves’ disease for Graves’ orbitopathy at each visit 
• Alert all patients with Grave’s disease to the risk of Graves’ orbitopathy 
• Prevent Graves’ orbitopathy - encourage smoking cessation, achieve and maintain 
euthyroidism quickly, avoid radioactive iodine (RAI) in active Graves’ orbitopathy, 
avoid hypothyroidism after RAI 
• Refer moderate and/or severe Graves’ orbitopathy to a specialist multidisciplinary clinic 
early 
 
 
 
 
 
Box 3: Treatments used for Graves’ orbitopathy 
 
Medical – immunosuppressive and immunomodulatory agents1,2,51,81,82 [Au: Please reference this 
statement.done]  
• Glucocorticoids 
• Orbital radiotherapy 
• Mycophenolate  
• Cyclosporine 
• Teprotumumab  
• Rituximab 
• Tocilizumab,  
• Emerging biological agents, such as Belimumab 
 
Medical non immunosuppressive
43
 [Au: Please reference this statement.done]  
• Selenium  
 
Surgery
2,141
 [Au: Please reference this statement.done]  
• Orbital bony decompression 
• Squint surgery 
• Lid surgery including Blepharoplasty or other reconstructive surgery 
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BOX 4: Rehabilitative Surgical management of Graves’ orbitopathy 
A variety of surgical options are available to treat Graves’ orbitopathy, depending on the nature 
of changes to the orbit. Lateral wall decompression, is the procedure of choice for the correction 
of proptosis of the globe if projection is <5mm. Persistent diplopia often requires squint surgery. 
The goals of surgery are to maintain binocular single vision in the primary position and on 
downgaze, meaning that patients will often have residual diplopia in other directions of gaze
142
. 
Finally, eyelid surgery in the form of blepharoplasty, lid lowering, midface lifting and brow fat 
pad reduction can be performed to remove bags and tighten the skin. Upper lid retraction can 
also be addressed with levator recession surgery
143
. [Au: Please reference this statement. done] 
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Table 1 Summary of key clinical trials since 2015 [Au: To define “recent” could you please 
provide a timeframe? In addition, I have flipped the table so that it fits within our style. I have 
left the text the same, unless marked with an Au:, but did remove the name of the authors to 
save space. Changes are fine have altered title of table] 
 
 
Agents studied Design N (year) Countries Follow 
up 
Key outcome 
assessed 
Key findings of trial Ref
s 
Tocilizumab 
 
Multi-centre double 
masked randomised 
trial 
32 
(2018) 
Spain 40 weeks Clinical activity 
score, EUGOGO 
ophthalmic score, 
Exophthalmos 
In glucocorticoid resistant GO 
tocilizumab resulted in 
substantial reduction in 
Clinical activity score, 
EUGOGO ophthalmic score 
and exophthalmos 
81
 
Teprotumumab 
 
Multicentre 
Randomised 
placebo controlled 
trial 
88 
(2017) 
USA, 
UK, 
Germany 
and Italy 
[Au: 
OK? 
fine]  
52 weeks Proptosis, Clinical 
activity score 
 
Substantial improvement in 
both proptosis and Clinical 
activity score  
73
 
Azathioprine, 
orbital 
radiotherapy 
Factorial design 
masked randomised 
control trial.  
126 
(2018) 
UK 24 weeks Composite 
outcome 
No benefit observed with 
radiotherapy. Potential benefit 
observed with Azathioprine 
29
 
Mycophenolate 
sodium  
Multicentre 
Observer masked 
randomised 
controlled trial IV 
Glucocorticoids vs 
IV Glucocorticoids 
plus Mycophenolate 
sodium 
164 
(2018) 
Germany 
and Italy 
12 weeks Composite 
outcome 
Addition of mycophenolate 
sodium significantly improved 
response rate at weeks 24 and 
36 
30
 
Mycophenolate 
Mofetil (MMF) 
Randomised trial of 
MMF vs IV methyl 
prednisolone and 
oral Glucocorticoids 
174 
(2016) 
China Treatme
nt of 24 
Weeks 
Clinical activity 
score, proptosis, 
and diplopia 
MMF superior to IV and oral 
glucocorticoids with regard to 
clinical activity score proptosis, 
diplopia and safety  
48
 
Rituximab Randomised double 
masked - IV methyl 
prednisolone vs 
Rituximab 
31 
(2015) 
Italy 52 weeks Clinical activity 
score 
Rituximab may be superior to 
IV methyl prednisolone 
76† 
Rituximab Randomised double 
masked, placebo-
controlled trial 
Rituximab versus 
placebo 
 24 
(2015) 
USA 52 weeks Clinical activity 
score 
No apparent benefit of 
Rituximab vs placebo 
75† 
 
N= Number of participants, IV = intravenous, MMF = Mycophenolate mofetil. †Differences in 
these trials may relate to Rituximab being only effective in early active disease 
29 
 
Table 2 Summary of newer [Au: newer requires a comparator, could this be changed to the date at 
which these agents were developed?] agent dosing and key monitoring requirements 
 
Agent Typical Doses Key monitoring and/or 
exclusion 
Mycophenolate
30,48,65
 360mg twice a day orally for 24 weeks 
(mycophenolate sodium) 
1 g twice a day for 24 weeks 
(mycophenolate mofetil)  
Monitor FBC, LFT 
Teprotumumab
73
 1 intravenous infusion of 10mg/Kg then 7 
infusions of 20mg/Kg. Infusion every 3 
weeks. Total treatment 24 weeks 
Monitor glucose, LFT 
Tocilizumab 
79,81
 Intravenous infusions of 8mg/Kg every 4 
weeks for 12 weeks. 
Monitor lipid profile, LFT, 
FBC and for demyelinating 
disorders. 
FBC = Full blood count  
LFT = Liver function test 
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Table 3 Current and Potential therapeutic targets 
 
Target Class of Therapy Mechanism of 
action 
Evidence of 
benefit 
Study 
Fibroblasts Glucocorticoids Reduced 
prostaglandin 
secretion, 
fibroblast activity, 
glycosaminoglycan 
production 
Pro-inflammatory 
cytokines 
+++ 
 
Zang
13
[Au: 
Can you 
please 
reference 
them 
here?added]  
Fibroblasts Prostaglandin F2 alpha 
(Bimatoprost) 
 Unclear Draman
83
 
Fibroblasts Mycophenolate 
sodium/Mycophenolate 
mofetil/Azathioprine  
Inhibition of 
PI3Kinase and 
mTOR pathways 
+ Rajendram, 
Taylor 
29
 
Kahaly 
30
 
Ye
48
 
Fibroblasts IGF-1 Receptor 
monoclonal antibody 
(Teprotumumab) 
Reduced PI3K 
activation and 
TSHR cross talk 
+++ Smith
73
 
T and B cells Glucocorticoids Inhibits 
proliferation and 
cytokine 
production 
+++ Zang
13,53
 [Au: 
Can you 
please 
reference 
them 
here?added] 
T and B cells Orbital radiotherapy Depletion, 
inhibits 
proliferation 
+ (as 
monotherapy) 
Prummel
56
  
T and B cells Mycophenolate 
sodium/Mycophenolate 
mofetil/Azathioprine 
Inhibits 
proliferation 
+ Rajendram, 
Taylor 
29
 
Kahaly 
30
 
Ye
48
 
B cells CD20 monoclonal 
antibody (Rituximab) 
B cell depletion, 
reduced antigen 
presentation  
++ Stan
75
 Salvi
76
 
IL6 Anti-IL6 receptor 
monoclonal antibody 
(Tocilizumab) 
Inhibits the pro-
inflammatory 
cytokine IL-6 
++ Perez-
Moreiras
79,81
 
Selenoproteins  Anti-oxidant Selenium ++† Marcocci 43 
 
† evidence-based use of selenium is limited to patients with newly onset, mild and active GO 
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Figure Titles and legends 
 
Figure 1 Proposed management of Graves’ Orbitopathy 
These guidelines have been adapted from the 2016 European Thyroid Association (ETA) 
Guidelines for the management of Graves’ Orbitopathy23. These recommendations were also 
integrated in the 2018 ETA guidelines for the management of Graves’ hyperthyroidism50. 
 
 
Figure 2 Overview of potential therapeutic targets in Graves’ Orbitopathy  
Disease mechanisms of Graves’ orbitopathy are indicated by dashed lines and pathogenesis red 
boxes. Existing and novel therapeutic candidates are represented by blue boxes and solid lines 
(see Table 2 for further information on mechanisms of action). *Potential therapeutic targets, 
Rapamycin, inhibitor of mTOR (mammalian target of rapamycin)
118
. TFP (trifluoperazine 
hydrochloride) to recruit FOXO repressors
121
. Other abbreviations: orbital adipose tissues 
(OAT); TSHR (T); IGF1 (I); TSHR auto-antibodies (TRAB); protein kinase A (PKA); 
phosphoinositide 3-kinase (PI3K); Tumor necrosis factor (TNF); Interleukin 6 (IL-6); small 
molecule (SM) antagonist; TSHR blocking antibodies (TBAB); Teprotumumab (TMB); 
Mycophenolate mofetil (MMF); Azathioprine (AZA); hyaluronan production (HA). 
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Glossary: 
 
Proptosis [G] Abnormal protrusion of the eyeball.  
 
Diplopia [G] Double Vision. 
 
Masked [G] Same as blinded in clinical trials, observer assessing outcomes does not know 
treatment allocation, masked is used instead of blinded in ophthalmology trials to not alarm 
patients ! 
 
Caruncular oedema [G] Oedema of the small, pink, globular nodule at the inner corner (the 
medial canthus) of the eye. 
  
Chemosis [G] Swelling and oedema of the conjunctiva 
 
Retrobulbar [G] Behind the eyeball 
